Klinische Forschung Berlin GbR
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Klinische Forschung Berlin GbR, investigators are exploring new strategies to improve outcomes for patients with heart failure and related cardiovascular risk factors.
- Heart failure with mildly reduced or preserved ejection fraction and systemic inflammation
- Hypercholesterolemia management with novel LDL‑C lowering agents
- Evaluation of anti‑inflammatory biologic therapy to reduce cardiovascular death and heart‑failure events
The site’s multidisciplinary team collaborates closely with cardiology specialists to bring innovative treatments to the clinic.
Virus Diseases
Research focuses on protecting healthy volunteers and at‑risk populations from influenza complications through vaccine immunogenicity and novel oral delivery systems.
- Immunogenicity comparison of high‑dose quadrivalent influenza vaccine in adults 50+ years
- Assessment of safety and antibody response using cell‑derived virus assays
- Evaluation of placebo‑controlled efficacy of nicotine mouthspray for e‑cigarette cessation, reducing respiratory viral risk
The Berlin site leverages its experience in infectious disease trials to support public‑health vaccination programs.
Pathological Conditions & Signs and Symptoms
Trials address lifestyle‑related conditions such as vaping cessation and metabolic disturbances, aiming to improve cessation rates and lipid profiles.
- Nicotine Freshmint Mouthspray effectiveness for e‑cigarette users seeking quit
- Novel oral peptide inhibitor MK‑0616 to lower LDL‑C in hypercholesterolemic participants
- Safety monitoring of investigational agents in stable comorbid populations
Klinische Forschung Berlin’s commitment to patient‑centered research ensures rigorous evaluation of emerging therapies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 102 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 99 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1AstraZeneca AB2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB8trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinische Forschung Berlin GbR
lock Showing 1 of 48 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 102 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Salbutamol | 5 | Unknown | 2021-04-25 | 2024-07-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.